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Association of Open-Angle Glaucoma Loci With Incident
Glaucoma in the Blue Mountains Eye Study
KATHRYN P. BURDON, PAUL MITCHELL, ANNE LEE, PAUL R. HEALEY, ANDREW J.R. WHITE,
ELENA ROCHTCHINA, PETER B.M. THOMAS, JIE JIN WANG, AND JAMIE E. CRAIG PURPOSE: To determine if open-angle glaucoma
(OAG)-associated single nucleotide polymorphisms
(SNPs) are associated with incident glaucoma and if
such genetic information is useful inOAGrisk prediction.
 DESIGN: Case-control from within a population-based
longitudinal study.
 METHODS: STUDY POPULATION: Individuals aged over
49 years of age living in the Blue Mountains region
west of Sydney and enrolled in the Blue Mountains Eye
Study. OBSERVATION: Cases for this sub-study (n [ 67)
developed incident OAG between baseline and 10-year
visits, in either eye, while controls (n[ 1919) had no ev-
idence for OAG at any visit. All participants had an
ocular examination and DNA genotyped for reported
OAG risk SNPs. MAIN OUTCOME MEASURE: Incident OAG.
 RESULTS: Two loci also known to be associated with
cup-to-disc ratio as well as OAG (9p21 near CDKN2B-
AS1 and SIX1/SIX6) were both significantly associated
with incident OAG in the Blue Mountains Eye Study
cohort (P [ .006 and P [ .004, respectively). The
TMCO1 locus was nominally associated (P [ .012),
while theCAV1/CAV2 and 8q22 loci were not associated.
Multivariate logistic regression and neural network anal-
ysis both indicated that the genetic risk factors contrib-
uted positively to the predictive models incorporating
traditional risk factors.
 CONCLUSIONS: This study shows that previously
reported genetic variations related to OAG and cup-to-
disc ratio are associated with the onset of OAG and thus
may become useful in risk prediction algorithms designed
to target early treatment to thosemost at risk of developing
glaucoma. (Am J Ophthalmol 2015;159:31–36.
 2015 The Authors. Published by Elsevier Inc. All
rights reserved. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/
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PEN-ANGLE GLAUCOMA (OAG) IS ONE OF THE
most common causes of blindness worldwide
and the number of affected individuals is ex-
pected to increase as the population ages.1 It is character-
ized by the progressive loss of retinal ganglion cells,
resulting in visual field defects beginning in the periphery
and progressing centrally.
Current guidelines for the Screening, Prognosis, Diag-
nosis, Management, and Prevention of Glaucoma2 state
that individuals at low risk of conversion from glaucoma
suspect or ocular hypertension to glaucoma should be
monitored, and those at high risk should be considered
for treatment. The determination of who is at risk is based
on a range of clinical risk factors, such as intraocular pres-
sure, migraine, family history, and central corneal thick-
ness.2 The genetic component of glaucoma risk is well
recognized. Several high-penetrance genes have been
described3,4 and genetic testing is available for some of
these.5 However, most patients do not carry mutations,
and thus the contribution of genetics in risk prediction is
currently limited to knowledge of family history, which is
notoriously unreliable.6
Several common genetic variants increasing the risk of
OAG have recently been identified through genome-
wide association studies (GWAS; Table 1). Three studies
of white individuals have collectively identified 5 loci.7–9
Loci reaching genome-wide significance levels include
TMCO1 on chromosome 1q24,7 CAV1/CAV28 on 7q31,
a regulatory region on 8q22,9 the 9p21 locus near
CDKN2B-AS1,7,9 and SIX1/SIX69 on 14q23. Several of
these loci have also been associated with OAG-related
quantitative traits, including intraocular pressure (IOP)
and vertical cup-to-disc ratio (VCDR). However, reports
from these cross-sectional studies did not distinguish
whether the SNPs are associated with the initiation or pro-
gression of OAG. Different genetic factors may be involved
with these 2 phases. Two of the loci (9p21 and TMCO1)
have been identified in an advanced OAG cohort, suggest-
ing they could be important in disease progression leading
to the observed enrichment in advanced disease. Both re-
gions are also associated with less severe OAG cases, indi-
cating they may also be important to the vulnerability to
OAG and its initiation.7
There have been no previous reports seeking to examine
genetic risk associated with the onset of OAG. To fill in
this gap of knowledge, we have undertaken an analysis in31ELSEVIER INC. ALL RIGHTS RESERVED.
TABLE 1. Published Genome-Wide Significant Single Nucleotide Polymorphism Associations With Open-Angle Glaucoma and
Associated Traits
Locus SNP (Allele) Gene Phenotype Country Results Reference
1q24 rs4656461(G) TMCO1 Advanced POAG Australia P ¼ 6.1 3 110
OR ¼ 1.68
Burdon et al7
rs755523(C) TMCO1 IOP Netherlands P ¼ 1.6 3 108
B ¼ 0.28
Van Koolwijk et al16
7q31 rs4236601(A) CAV1/CAV2 POAG Iceland P ¼ 5.0 3 1010
OR ¼ 1.36
Thorleifsson et al8
8q22 rs1521774(G) Gene desert NTG USA P ¼ 1.35 3 109
OR ¼ 0.62
Wiggs et al9
9p21 rs4977756(A) CDKN2B-AS1 Advanced POAG Australia P ¼ 4.7 3 109
OR ¼ 1.50
Burdon et al7
rs1412829(T) CDKN2B-AS1 POAG Australia P ¼ 2.93 3 1010
OR ¼ 1.45
Burdon et al7
rs1063192(G) CDKN2B POAG USA P ¼ 2.30 3 2017
OR ¼ 1.43
Wiggs et al9
VCDR Netherlands P ¼ 1.96 3 1014
B ¼ 0.014
Ramdas et al17
14q22 rs10483727(A) SIX1/SIX6 POAG USA P ¼ 3.87 3 1011
OR ¼ 1.32
Wiggs et al9
VCDR Netherlands P ¼ 9.30 3 1011
B ¼ 0.012
Ramdas et al17
B¼ beta; IOP¼ intraocular pressure; NTG¼ normal tension glaucoma; OR¼odds ratio;P¼ P value; POAG¼ primary open-angle glaucoma;
SNP ¼ single nucleotide polymorphism; VCDR ¼ vertical cup-to-disc ratio.an older Australian cohort from the Blue Mountains Eye
Study (BMES), to determine whether genetic analysis
could inform on the likelihood of an individual’s being
diagnosed with glaucoma in the future. The BMES is a
well-known longitudinal population-based study of
ophthalmic health and disease that includes baseline and
5-year and 10-year follow-up data. This population is
considered to be stable, homogeneous, and representative
of the Australian population, but older compared to the
average for the state of New South Wales, where it was
recruited.10METHODS
THE BLUE MOUNTAINS EYE STUDY WAS APPROVED BY THE
Human Research Ethics Committee of the University of
Sydney for investigation of the epidemiology and genetics
of ocular disease. The BMES has been described previ-
ously.10 Briefly, the BMES is a population-based study of in-
dividuals living in the Blue Mountains region west of
Sydney, Australia. Any permanent, noninstitutionalized
resident of the defined geographic region born before
January 1, 1943 (aged over 49 years at time of recruitment)
and able to give written informed consent was eligible for
enrollment in BMES and was contacted by door-to-door
canvassing. Participants underwent a baseline visit,
with follow-up at 5 years and at 10 years. At baseline, all32 AMERICAN JOURNAL OFparticipants received a detailed eye examination, including
applanation tonometry, suprathreshold automated perime-
try (Humphrey 76-point test, followed by 30-2 fields
[Humphrey Visual Field Analyser 630 with StatPac 2,
Humphrey Instruments, Inc, San Leandro, California,
USA]), and stereoscopic optic disc photography (Carl Zeiss
Australia, Sydney, New South Wales, Australia). The cur-
rent sub-study consisted of a case-control design from
within the BMES cohort study. Participants with normal
threshold or suprathreshold field tests and no sign of glau-
coma at the baseline visit were included in the current
study. Participants with OAG at baseline (prevalent
OAG) were excluded. As previously reported,11 incident
OAG cases were defined as participants free of OAG at
baseline who showed glaucomatous field loss on full-
threshold perimetry (Humphrey 24-2 or 30-2), which
matched the optic disc appearance, at either the 5-year
or 10-year follow-up visit, without reference to intraocular
pressure. Patients with pseudoexfoliation syndrome were
not excluded (n ¼ 7). DNA was extracted from peripheral
whole blood using standard techniques. Genotyping was
performed on the HumanHap670 array (Illumina, San
Diego, California, USA) as part of the Wellcome Trust
Case Control Cohort 2 Genome-Wide Association Study.
Data were cleaned and genotypes called as previously
described.12 No significant population stratification was
detected in this population.12
Single nucleotide polymorphisms (SNPs) were selected
for analysis if they had been previously reported to beJANUARY 2015OPHTHALMOLOGY
TABLE 2. Baseline Characteristics of the Eligible Blue






Sex (% female) 73% 57% .009
Age 68.9 6 7.9 63.8 6 8.3 <.001
Mean IOP (mm Hg) 17.6 6 2.8 15.9 6 2.6 <.001
Mean VCDR 0.53 6 0.11 0.42 6 0.12 <.001
Mean DD (mm) 1.52 6 0.18 1.51 6 0.17 .570
Systolic BP (mm Hg) 151.6 6 21.2 144.0 6 20.4 .005
Diastolic BP (mm Hg) 85.7 6 9.5 83.4 6 9.6 .053
BP ¼ blood pressure; DD ¼ disc diameter; IOP ¼ intraocular
pressure; OAG ¼ open-angle glaucoma; VCDR ¼ vertical cup-
to-disc ratio.
Data presented as mean 6 standard deviation.associated with OAG (including normal tension glau-
coma) at genome-wide significance in white populations.
The reported SNPs with the smallest P values at each locus
were chosen for this analysis. In the case of the 9p21 locus
reported independently in 2 papers,7,9 the top SNP from
each paper was chosen, as well as a third SNP at genome-
wide significance in the replication cohorts of Burdon
and associates (rs1412829).7 We hypothesize that if this
SNP had been typed in the discovery cohort for this study,
it would likely have been the top-ranked SNP at this locus.
Seven SNPs at 5 loci were chosen for analysis in total.
Power calculations were conducted with the Genetic Po-
wer Calculator.13 This study had 77% power to detect an
association at a SNP with an allele frequency of 30% and
an odds ratio of 1.6 under an additive model at a P value
of .007, assuming a population disease prevalence of
5.67%.14 These parameters are similar to those reported
for most of these loci in cross-sectional studies of OAG ge-
netics.
Differences in the demographics of the available cohort
were assessed using IBM SPSS Statistics V20. Association
analysis was conducted under a univariate allelic model
and also using logistic regression under an additive model
adjusted for baseline measurements of age, sex, mean IOP
of both eyes, mean cup-to-disc ratio of both eyes, mean
disc diameter of both eyes, and systolic and diastolic blood
pressure using Plink.15 Statistical significance was set to P
< .007 under a Bonferroni correction, to account for the 7
SNPs tested. One associated SNP from each significant or
nominally significant locus and the clinical variables were
included in a logistic regressionmodel using IBMSPSS Sta-
tistics V20. SNPs were coded to the number of OAG risk al-
leles carried by each participant at each SNP (0, 1, or 2).
Collinearity between variables in the model were assessed
by calculating the tolerance and the variance inflation fac-
tor (VIF). No collinearity was detected (no VIF >2).
The rank importance of each model component was also
assessed using a large population of neural networks (pro-
duced using Matlab; The MathWorks, Inc, Natick, Massa-
chusetts, USA). A neural network can be thought of as a
small machine capable of learning. It is trained by exposure
to a dataset comprising inputs (for example, the character-
istics of horses in a race) and outputs (the winning horse).
After each round of training, the link strengths within the
network are changed, and further training is undertaken
until its predictive performance on a previously unseen
‘‘validation’’ dataset no longer improves. The resulting net-
work’s performance is then measured using a final, also un-
seen ‘‘test’’ dataset. In this study, each neural network drew
its inputs from unique subset of 7 SNPs and 7 clinical vari-
ables (age, sex, diastolic and systolic blood pressure, cup-to-
disc ratio, IOP, and disc diameter). To cover all possible
permutations of these 14 inputs, 16 383 neural networks
were required.
Each neural network was trained and tested with a
cohort comprising glaucoma patients (n¼ 67) and an equalVOL. 159, NO. 1 GLAUCOMA-ASSOCIATED POLYMORPHnumber of randomly selected controls: 70% of the cohort
was used to train the network, 15% to validate its perfor-
mance during training, and the remaining 15% were un-
seen during training and were used to test the final
performance of each network. Each neural network was
trained and tested 20 times. In separate analyses, controls
were either age matched to within 2 years of incident cases
or not age matched. An error score was calculated to
describe the performance of each neural network: the error
score was the proportion of cases incorrectly classified (as
glaucoma or as not glaucoma) by the network. Ranking
of the importance of input variables (clinical parameters
and SNPs) was achieved by ranking their influence on neu-
ral network error score. If the presence of a particular SNP
or clinical variable (among the neural network’s input vari-
ables) reduced the error score, that SNP or variable can be
considered to make a positive contribution to the perfor-
mance of the network (ie, it is of useful predictive value).RESULTS
THE BMES COHORT CONSISTED OF 1986 INDIVIDUALS WITH
follow-up phenotype data at either the 5-year, 10-year, or
both visits with genotypes available (Table 2). Of the
1986 participants, there were 67 incident OAG cases
over the full 10-year follow-up period. At baseline, the inci-
dent OAG cases were significantly older than controls (P<
.001) and had a higher proportion of female subjects (P ¼
.009). IOP and VCDR at the baseline visit were also signif-
icantly different between those who later developed OAG
and those who did not (Table 2), as was systolic blood pres-
sure. These features of this cohort have been previously
reported.11
Association analysis indicates that incident OAG was
associated with SNPs at 3 of the 5 loci tested (Table 3).33ISMS AND INCIDENT GLAUCOMA
TABLE 3.Association of Genome-Wide Significant Open-Angle Glaucoma LociWith 10-Year Incident Glaucoma in the BlueMountains
Eye Study
Locus CHR SNP Position (bp)a A1/A2
Frequency A1 Univariate Analysis Multivariate Analysisb
Cases Controls P Value OR (95% CI) P Value OR (95% CI)
TMCO1 1 rs4656461 163953829 G/A 0.187 0.116 .013 1.74 (1.12–2.72) .022 1.79 (1.09–2.95)
CAV1/CAV2 7 rs4236601 115949965 A/G 0.313 0.268 .239 1.25 (0.86–1.81) .329 1.21 (0.82–1.78)
8q22 8 rs1521774 106048166 G/A 0.366 0.324 .314 1.20 (0.84–1.72) .443 1.16 (0.80–1.67)
9p21 9 rs1063192 21993367 A/G 0.642 0.549 .033 1.47 (1.03–2.11) .103 1.37 (0.94–2.01)
9p21 9 rs1412829 22033926 A/G 0.687 0.568 .006 1.67 (1.15–2.42) .025 1.57 (1.06–2.32)
9p21 9 rs4977756 22058652 A/G 0.687 0.591 .027 1.52 (1.05–2.20) .109 1.37 (0.93–2.02)
SIX1/SIX6 14 rs10483727 60142628 A/G 0.508 0.384 .004 1.66 (1.17–2.34) .007 1.70 (1.16–2.50)
A1 ¼ allele 1; A2 ¼ allele 2; CHR ¼ chromosome; CI ¼ confidence interval; OR ¼ odds ratio; SNP ¼ single nucleotide polymorphism.
aSNP positions are given in genome assembly hg18 in base pairs (bp). All analyses are with respect to the reported open-angle glaucoma risk
allele (A1).
bMultivariate analysis is adjusted for baseline characteristics age, sex, mean intraocular pressure, cup-to-disc ratio and disc diameter of both
eyes, and systolic and diastolic blood pressure.
TABLE 4. Logistic RegressionModel Showing Association of
Each Clinical Variable and Associated Polymorphism With
10-Year Incident Open-Angle Glaucoma in the Blue
Mountains Eye Study
Variable B SE P Value OR (95% CI)
Female sex 0.930 0.305 .002 2.53 (1.39–4.61)
Age (y) 0.064 0.017 <.001 1.07 (1.03–1.10)
Mean IOP (mm Hg) 0.217 0.048 <.001 1.24 (1.13–1.36)
Mean VCDR 0.827 0.135 <.001 2.29 (1.76–2.98)
Mean DD (mm) 1.803 0.838 .031 0.17 (0.03–0.85)
Systolic BP (mm Hg) 0.005 0.008 .559 1.00 (0.98–1.01)
Diastolic BP (mm Hg) 0.021 0.018 .245 1.02 (0.99–1.06)
rs4656461 (no. of
risk alleles)
0.608 0.258 .018 1.84 (1.11–3.04)
rs1412829 (no. of
risk alleles)
0.439 0.205 .032 1.55 (1.04–2.32)
rs10483727 (no. of
risk alleles)
0.525 0.200 .009 1.69 (1.14–2.50)
Constant 16.221 2.348
B ¼ maximum likelihood estimate; BP ¼ blood pressure;
CI ¼ confidence interval; DD ¼ disc diameter; IOP ¼ intraocular
pressure; OR ¼ odds ratio; SE ¼ standard error of B;
VCDR ¼ vertical cup-to-disc ratio.
TABLE 5. Neural Network Ranking and Contribution to Risk
Prediction of Variables Associated With 10-Year Incident
Open-Angle Glaucoma Risk in the BlueMountains Eye Study
Rank
Age Matched Not Age Matched
Variable Contributiona Variable Contributiona
1 Mean VCDR 0.034777 Mean VCDR 0.041231
2 Mean IOP 0.030919 Age 0.031223
3 Female sex 0.008209 Mean IOP 0.028952
4 rs4656461 0.007138 rs10483727 0.004189
5 Diastolic BP 0.004934 Diastolic BP 0.004119
6 rs10483727 0.001923 Systolic BP 0.004102
7 rs4236601 0.001604 rs4656461 0.003295
8 rs1412829 0.000489 rs1412829 0.001517
9 Systolic BP 0.00073 Mean DD 0.00070
10 Mean DD 0.00084 rs4236601 0.00224
11 rs4977756 0.00228 Sex 0.00249
12 rs1063192 0.00481 rs1063192 0.00361
13 rs1521774 0.00552 rs4977756 0.00408
14 Age 0.00748 rs1521774 0.00922
BP ¼ blood pressure; DD ¼ disc diameter; IOP ¼ intraocular
pressure; VCDR ¼ vertical cup-to-disc ratio.
aThe contribution of each variable is defined as the reduction in
neural network predictive error it confers.Significant association under an allelic test was seen at
rs1412892 (P ¼ .006) at the 9p21 locus as well as
rs10483727 (P ¼ .004) at the SIX1/SIX6 locus. Additional
SNPs at 9p21 and also at TMCO1 were nominally signifi-
cant but did not survive after correction for multiple com-
parisons. The SNPs at the 8q22 and CAV1/CAV2 loci did
not show association with incident glaucoma. Adjustment
for covariates under an additive genetic model showed as-
sociation at the same SNPs, although only SIX1/SIX6
remained significant after correction for testing 7 SNPs
(P <_ .007) (Table 3).34 AMERICAN JOURNAL OFWhen all covariates and the 3 associated loci (TMCO1,
9p21, and SIX1/SIX6) were included in a single regression
model, all variables except blood pressure contributed
significantly to the model (Table 4).
The population of neural networks was used to compare
the rank importance of variables in the predictive model
both with and without age matching between controls
and incident cases (Table 5). As expected, when not age
matched, vertical cup-to-disc ratio, age, and intraocular
pressure rank the highest for predicting incident OAG.JANUARY 2015OPHTHALMOLOGY
The top-ranked SNP in this analysis is at the SIX1/SIX6 lo-
cus, which also showed the strongest genetic association.
When cases and controls were closely age matched the
rank order of variables changed, likely indicating an inter-
action between age and the other variable, although verti-
cal cup-to-disc ratio and intraocular pressure are still the
most predictive variables. In this situation the SNP at
the TMCO1 locus was most predictive. Of note, in both
analyses, all SNPs significantly associated with incident
OAG under the traditional statistics contribute positively
to the neural network and improve its ability to predict
incident OAG.
DISCUSSION
THE SELECTED LOCI HAVE BEEN DISCOVERED THROUGH
genome-wide association studies for OAG (SIX1/SIX6,
CAV1/CAV2),8,9 advanced OAG (9p21, TMCO1),7 or
normal tension glaucoma (9p21, 8q22).9 In addition, vari-
ation at TMCO1 has been associated with intraocular
pressure,16 while 9p21 and SIX1/SIX6 are associated with
cup-to-disc ratio17 in normal individuals. We provide evi-
dence for association at SIX1/SIX6, 9p21, and nominally
at TMCO1 with incident OAG. Thus, loci associated
with advanced glaucoma and relevant biometric traits are
also associated with the initial onset of OAG (incidence).
Those SNPs discovered in previous cohorts with typical
(nonadvanced) OAG are not found to be associated with
OAG incidence in our cohort, although power to detect
weaker associations or those at rarer SNPs is limited. The
association of sex with incident OAG in the cohort has
been previously reported,11 as has the higher-than-
expected level of hypertension in the BMES cohort.18,19
The current cohort was sufficiently powered to detect an
odds ratio ofw1.6. This is larger than those observed in the
original discovery cohorts of cross-sectional (prevalent
OAG) patient recruitment, although significant effects
were still observed in this study, suggesting that the SNPs
may be more important in predicting disease onset than
progression, or that the true effect size is larger than previ-
ously reported. However, larger prospective cohorts will be
needed to properly assess the 8q22 andCAV1/CAV2 loci in
particular.
A nominal association was observed at TMCO1. This
SNP has a lower allele frequency than others in the study
(11% in controls) and the finding did not reach signifi-
cance here in the context of multiple testing, owing to
the lower power of this study (w36%) to detect an effect
at the minor allele frequency of 11%. We have previously
reported an association of this locus with prevalent OAG
in the BMES cohort with odds ratio (OR) ¼ 1.57, P ¼
.022.7 The odds ratio for incidentOAG reported in the cur-
rent study was larger (OR ¼ 1.74, P ¼ .013) despite the
smaller sample size. We thus conclude that TMCO1 is
also confirmed to be associated with incident OAG.VOL. 159, NO. 1 GLAUCOMA-ASSOCIATED POLYMORPHThe current study shows that OAG loci that are associ-
ated with OAG-relevant ocular parameters (cup-to-disc
ratio and intraocular pressure) are specifically associated
with OAG incidence independently of other known risk
factors. This suggests that these loci are responsible at least
in part for the initiation of OAG, consistent with their role
in determination of these risk factor traits, which are them-
selves predictive for OAG development.We show also that
the loci specifically associated with advanced glaucoma
may also be important in initiation of OAG, and thus could
be important in risk stratification among glaucoma suspect
and early glaucoma patients.
The multivariate logistic regression model indicates that
mean vertical cup-to-disc ratio at baseline is by far the most
significant predictor of incident glaucoma in this cohort,
while in the context of other parameters blood pressure
contributes almost nothing to this model. Although verti-
cal cup-to-disc ratio is a well-recognized parameter in the
prediction of OAG risk, the accuracy of prediction based
solely on this parameter is poor owing to disc appearance
in preclinical and early glaucomatous damage overlapping
with the normal range of this trait. Predictive accuracy for
the individual patient should be improved by the inclusion
of other variables, including genetics. With the genetics
tools available at this time, discriminatory power above
and beyond that achievable with clinical risk factors is min-
imal; however, ongoing research uncovering the genetic
basis of OAG is likely to lead to better risk prediction
models.
Neural networks allow an alternative approach to esti-
mating the usefulness of clinical and genetic variables in
predicting incident glaucoma. Input variables that are pre-
dictive of incident glaucoma naturally benefit the perfor-
mance of the network. However, we see that those
variables of trivial or no predictive value negatively affect
the performance of the network: their inclusion necessarily
makes the network structure more complex, which will
lead to increased noise in the network. Neural networks
are therefore helpful in distinguishing those patient charac-
teristics that might help the clinician to predict glaucoma
incidence and those that will merely overload him or her
with unhelpful information. This approach could easily
be expanded to larger datasets where specific combinations
of variables that are particularly beneficial might become
apparent. The matching of age (an important OAG risk
factor) between cases and controls in the neural network
analysis resulted in the TMCO1 SNP, rs4656461,
becoming the highest-ranked genetic variable. This is
consistent with a previously reported finding of the associ-
ation of this SNP with age of onset of OAG.20
Each of the associated SNPs in the logistic regression
model also contributed positively in the neural network.
Thus, the combination of IOP, disc parameters, and geno-
type at-risk SNPs could improve the accuracy of OAG risk
prediction, which in turn will inform early treatment deci-
sions for those most likely to develop this blinding disease.35ISMS AND INCIDENT GLAUCOMA
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